Image Source: The Hill
Critical Details on the Cetirizine Recall
In a shocking development for allergy medication users, a cetirizine recall has been announced due to potential contamination risks. New Jersey-based Rising Pharma Holdings Inc. recently issued a recall on July 18 for specific lots of cetirizine hydrochloride tablets, which are commonly utilized for treating seasonal allergies and hives. The recall raises serious health concerns as the medication may have been cross-contaminated with ranitidine, a drug used to treat heartburn, acid indigestion, and other gastric issues.
The Manufacturer and Reason for Recall
The cetirizine tablets in question were produced by Unique Pharmaceutical Laboratories, based in India, and distributed by Rising Pharma. The contamination was discovered when a pharmacy technician noted an unusual red dot on several tablets during a routine count. According to the Food and Drug Administration (FDA), this issue has the potential to cause life-threatening side effects, particularly in consumers sensitive to ranitidine.
Identification of Recalled Products
Consumers looking to identify the recalled cetirizine hydrochloride tablets should be aware of the following details:
- Manufacturer: Unique Pharmaceutical Laboratories (a division of J.B. Chemicals & Pharmaceuticals Ltd.)
- Distributor: Rising Pharma Holdings Inc.
- National Drug Code No.: 16571-401-10
- Expiration Date: 10/2028
- Lot Numbers: GY825029, GY825030, GY825031, GY825032
The recalled products come in 100-count bottles, and customers are urged to check their medicine cabinets for any affected lots. The recall has been officially communicated via email to distributors and customers by Rising Pharma.
Health Risks Associated with Contaminated Tablets
Although Unique Pharmaceutical Laboratories reported no adverse effects linked to the contaminated tablets thus far, the potential for serious health complications remains high. Consumers who are hypersensitive to ranitidine may face severe reactions, including:
- Anaphylaxis
- Difficulty swallowing
- Swelling of the throat or face
- Shortness of breath
- Low blood pressure
- Hives or itchiness
Healthcare experts are advising that any users of these contaminated products contact their physician immediately if they experience any concerning symptoms.
Customer Guidance and Contact Information
Customers who may have purchased these recalled tablets can reach out to Rising Pharma Holdings for assistance between 8 a.m. and 5 p.m. Eastern time, Monday through Friday, at 1-844-874-7464. Additionally, they can send an email to the company for further inquiries. It is advisable for all affected consumers to report adverse reactions or quality issues through the FDA’s MedWatch Adverse Event Reporting program.
In light of the rising concerns over this cetirizine recall, awareness and prompt action will be crucial in preventing any potential health emergencies linked to the contaminated medications.
Frequently Asked Questions
What is the main reason for the cetirizine recall?
The recall was issued due to concerns that cetirizine hydrochloride tablets may be contaminated with ranitidine, posing potential health risks.
How can I identify the recalled cetirizine products?
Look for the product’s National Drug Code No. 16571-401-10 and check for the lot numbers GY825029, GY825030, GY825031, and GY825032.
What should I do if I have the recalled tablets?
If you possess any of the recalled medications, do not consume them and contact your physician or Rising Pharma Holdings for guidance.
Are there any reported adverse effects from the contaminated tablets?
As of now, there have been no reported adverse effects, but the potential risks include severe reactions for those sensitive to ranitidine.
How can I report any adverse reactions I experience?
Consumers can report adverse reactions or quality problems to the FDA through the MedWatch Adverse Event Reporting program.
